Table 2.

Representative clinical trials using IN administration for CNS disease management.

Condition	NCT number	Phase	Intervention	Status	Ref.
Alcoholism	NCT03339024	Phase III	Repeated IN administration of oxytocin spray twice a day for 30 days	Completed	93
	NCT01829516	Phase IV	Single IN administration of oxytocin	Completed	N/A
Schizophrenia	NCT00575666	Phase IV	Repeated IN administration of insulin 4 times a day	Completed	N/A
	NCT03245437	Phase IV	Oxytocin nasal spray	Completed	N/A
Alzheimer's disease	NCT01767909	Phase II/III	Daily IN administration of insulin for 12 months	Completed	94
Treatment-resistant depression	NCT02497287	Phase III	Repeated IN self-administration of esketamine twice a week for 4 weeks	Completed	81
Ischemic stroke	NCT03686163	Phase IV	Daily IN administration of NGF for 2 weeks	Completed	N/A
Epilepsy	NCT01999777	Phase III	Single IN administrated of midazolam	Completed	95

Resource of the clinical trial is from ClinicalTrials.gov.

IN, intranasal; NGF, nerve growth factor; N/A, not applicable.